Aged care operator Oceania Healthcare (ASX:OCA) grew sales, grew earnings and cut debt – but pulled its dividend

EBITDA up 20% and gearing at the low end of target, yet operating cash flow stays negative.

Oceania Healthcare (ASX:OCA), a residential aged care operator based in Auckland, just posted its FY26 result. The company, which follows an April to March financial year, is calling a record FY26 result on the basis that its Proforma Underlying EBITDA is NZ$97.7m – up 20% on the prior year. Moreover, sales volumes lifted 16% to 603 units, and net debt fell NZ$121.4m to NZ$506.7m. On the surface this looks like a clean turnaround story.

But here’s where investors will be seething: the Board has said no FY26 dividend will be paid. That is the line that frames how investors should read the rest of the result. The cash story is improving fast, but it is not yet positive.

OCA’s Free Cash Flow from Operations was still an outflow of NZ$15.0m for the year. That is a 64% improvement on FY25, and management has guided to positive operating free cash flow in FY27. Until that switch actually flips, the dividend stays parked, and Oceania remains a turnaround in progress rather than a yield name.

The cost-out program is doing real work, not just optics

Oceania pulled NZ$13.2m of cost savings out of the business in FY26 and has the run rate set up to deliver NZ$20.4m of annualised savings in FY27. Support office headcount costs are down roughly 20%. A further ~NZ$30m of total cash and cost savings is targeted in FY27 from working capital, lower stock levels and capex discipline.

Care EBITDA per occupied bed jumped 40% to NZ$27k. Strip out development and resale gains and underlying care profitability still climbed 43%, which tells us the operational lift is not just a property cycle artefact. The premiumisation strategy, essentially shifting the portfolio toward larger integrated villages and higher-margin care suites, is showing up in the unit economics.

We think this is the most important part of the result. The 20% EBITDA growth would mean less if it were just driven by volume, but the margin improvement per occupied bed is the kind of structural progress that compounds.

Unsold stock down 34% changes the working capital picture

Unsold inventory dropped by NZ$115m to NZ$227m, a 34% reduction even after NZ$79m of new units were added during the year. Resales were up 20% with 402 units settled, delivering NZ$37m of gains. The Helier in Auckland is 74% sold or under application and is closing in on full development cost recovery including interest at 97%.

The Franklin Village Stage 1 launch has 80% of its 31 villas sold or under application, and Stage 2 enabling works have already started. The FY27 build rate steps up modestly to 81 new units across Franklin, Bream Bay and Elmwood.

The skeptical read is that this was achieved against a subdued NZ residential property market, which means any genuine cyclical recovery could accelerate the cash conversion materially. Equally, if the property market stays soft, the path back to dividends could slip.

Gearing at 30.1% buys breathing room the prior balance sheet did not have

The company’s NZ$506.7m net debt figure and its 30.1% gearing level puts Oceania at the lower end of its 30% to 35% target range. NZ$51.1m of divestment proceeds from seven sites went straight to core debt. Total assets sit at NZ$3.1bn and NTA improved 7.3% to NZ$1.62 per share.

The company’s chair Liz Coutts effectively framed the balance sheet as a defensive posture given current economic uncertainty and the slow property market. That is a fair read. It also means Oceania has optionality, both to ride out further weakness and to lean into selective growth without going back to shareholders.

The Investors Takeaway for Oceania Healthcare

Oceania has done the hard work on costs, portfolio refinement and balance sheet repair. The setup into FY27 looks materially stronger than the setup into FY26, and the operational metrics are pointing the right way. NTA of NZ$1.62 also gives valuation-focused investors a clear anchor.

We believe the single catalyst that will re-rate this stock will be the move to positive Free Cash Flow from Operations, because that should trigger the dividend reinstatement under the 40% to 60% payout policy. Investors should watch the 1H FY27 result (due in November) for the first read on whether the NZ$15m outflow has genuinely flipped. For broader context on ASX-listed aged care and retirement names, see our coverage at stocksdownunder.

Get that flip and Oceania goes from turnaround story to income story in a single reporting period. Miss it and the patience of holders gets tested again.